M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: HC-7366
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2024-02-29

Last Posted Date: 2025-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT06285890

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Revumenib

First Posted Date: 2024-02-29

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT06284486

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Phase 3

Recruiting

Conditions: Prostatectomy
Androgen Axis Suppression
Prostate Cancer

Interventions: Drug: Androgen Deprivation Therapy
Drug: Apalutamide

First Posted Date: 2024-02-23

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT06274047

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Phase 2

Recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Pirtobrutinib

First Posted Date: 2024-02-16

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT06263491

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Phase 2

Recruiting

Conditions: Hematopoietic
Familial Platelet Disorder

Interventions: Drug: Sirolimus

First Posted Date: 2024-02-15

Last Posted Date: 2024-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT06261060

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Understanding Patient Experience Among Asians At MD Anderson

Recruiting

Conditions: Cancer

First Posted Date: 2024-02-14

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 520

Registration Number: NCT06259253

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

Phase 2

Recruiting

Conditions: ICB-refractory Melanoma

Interventions: Other: Prebiotic Food-Enriched Diet
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2024-02-09

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT06250335

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Lung Neoplasms
Advanced Solid Tumor
Melanoma
Head and Neck Neoplasms

Interventions: Drug: KSQ-001EX
Drug: Cyclophosphamide
Drug: Interleukin-2
Drug: Fludarabine

First Posted Date: 2024-02-02

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT06237881

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Myeloid Leukemia

Interventions: Drug: Gilteritinib
Drug: Momelotinib

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06235801

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Phase 2

Recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Asciminib

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT06236724

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy